Get informed when a big investor buys or sells
+ FollowOvervalued by 140.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $33.00 Million |
|---|---|
| Enterprise Value | $27.89 Million |
| Earnings per Share | $-0.02 |
| Beta | 0.59 |
| Outstanding Shares | 284,016,013 |
| P/E Ratio | -13.03 |
|---|---|
| PEG | -112.59 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 34.76 |
| Enterprise Value to EBIT | -7.38 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Theralase Technologies Inc., founded in Toronto, Canada in 1994, is a clinical-stage pharmaceutical company focused on the development of innovative therapies and medical devices. The company's pharmaceutical division specializes in the ...